ArticleEuropean journal of medical research2024
Association of triglyceride glucose-body mass index and left ventricular hypertrophy in patients with IgA nephropathy: a retrospective study.
Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Visceral Obesity and Metabolic Dysfunction in IgA Nephropathy: Nutritional and Metabolic Perspectives on Disease Progression.Nutrients · 2025Pooled it
- Impact of epicardial adipose tissue volume and hypertension on left ventricular hypertrophy in preclinical heart failure patients with metabolic syndrome.BMC cardiovascular disorders · 2025Article
- Association between the triglyceride-glucose-waist-to-height ratio and early arterial stiffness in cardiovascular-kidney-metabolic syndrome.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIgA nephropathy (IgAN) is one of the most prevalent forms of glomerulonephritis worldwide, particularly affecting 40-50% of the East Asian population. Cardiovascular mortality represents a leading cause of death in patients with IgAN. Left ventricular hypertrophy (LVH) serves as a predictor of heart failure and cardiovascular mortality. Previous studies have indicated that Triglyceride glucose-body mass index (TyG-BMI), a surrogate marker for insulin resistance surrogates, correlated with the development of LVH. However, there is a lack of information available regarding the association between TyG-BMI and LVH in patients with IgAN. This study aims to explore the relationship between TyG-BMI and LVH in this population.
methodsThis retrospective study was conducted in the Fifth Affiliated Hospital of Sun Yat-sen University recruiting inpatients with renal biopsy-confirmed IgAN who were over the age of 18 years. Left ventricular dimensions were assessed through echocardiography. Linear regression and multivariate logistic regression analyses were performed using R language software and SPSS to investigate the association between TyG-BMI levels and LVH risk. Statistical significance was set at p < 0.05.
resultsA total of 327 patients with IgAN were enrolled in this study. Left ventricular mass index (LVMI) was positively correlated with TyG-BMI index (corr. coefficient: 0.453, p < 0.001) and inversely correlated with eGFR (corr. coefficient: -0.392, p < 0.001). After adjusting for age, gender, smoking, alcohol use, hemoglobin, low-density lipoprotein cholesterol, Scr, and urine output, advanced age and higher levels of hemoglobin and Scr were independently associated with increased TyG-BMI (p < 0.05). The odds ratios of the highest quartile of TyG-BMI compared with the lowest quartile were 8.39 (95%CI 1.66-42.39; p = 0.010).
conclusionsOur findings indicated that the TyG-BMI level was positively correlated with LVMI. A high TyG-BMI level was independently associated with an increased risk of LVH in patients with IgAN. TyG-BMII demonstrated predictive ability for LVH in IgAN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.